Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy

20122,766 citationsJournal Articlehybrid Open Access

Authors

Charles J. Ryan · UCSF Helen Diller Family Comprehensive Cancer Center

Matthew R. Smith · Massachusetts General Hospital

Johann S. de Bono · Royal Marsden Hospital

Arturo Molina · Janssen (Belgium)

Christopher J. Logothetis · The University of Texas MD Anderson Cancer Center

Paul de Souza · St. George Hospital

Karim Fizazi

Abstract

Abiraterone improved radiographic progression-free survival, showed a trend toward improved overall survival, and significantly delayed clinical decline and initiation of chemotherapy in patients with metastatic castration-resistant prostate cancer. (Funded by Janssen Research and Development, formerly Cougar Biotechnology; ClinicalTrials.gov number, NCT00887198.).

Topics & Keywords

Prostate Cancer Treatment and Research Prostate Cancer Diagnosis and Treatment Hormonal and reproductive studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 368, Issue 2, pp. 138-148

DOI: 10.1056/nejmoa1209096

Field-Weighted Citation Impact: 176.96